Jiangsu Nhwa Pharmaceutical (002262.SZ) has obtained the Drug Registration Certificate for Hydrobromide Fosinopril tablets.

Jiangsu Nhwa Pharmaceutical (002262.SZ) announced that the company has recently obtained the "Drug Registration Certificate" for the chemical drug Hydrobromide fluoxetine tablets issued by the National Medical Products Administration. Hydrobromide fluoxetine tablets are used to treat adult depression. The acquisition of the "Drug Registration Certificate" for Hydrobromide fluoxetine tablets enriches the company's product pipeline in the central nervous system field, which will help improve the company's market competitiveness. The listing and sales of this product will have a positive impact on the company's future performance.